Impact of Aronia Berry Consumption on Inflammation, Metabolites, and the Gut Microbiome

Inflammation Clinical Trial

Official title:

Antioxidant-rich Aronia Supplementation Impacts Human Metabolism and Immune Response as Well as Gut Microbiome Metabolism

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05255718
• Other study ID #: NIFA 2017-67018-26367
• Secondary ID: MC010819
• Status: Completed
• Phase: N/A
• Start date: April 27, 2019
• Est. completion date: August 18, 2019

Study information

• Verified date: March 2024
• Source: Montana State University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of this project is to elucidate interactions between the gut microbiome, anti-inflammatory/anti-oxidant food metabolomic signatures, and human inflammation phenotypes. Inflammation plays both direct and indirect roles in the development of type 2 diabetes (T2D), atherogenic cardiovascular diseases, and other causes of morbidity and mortality. Aronia melanocarpa (Aronia berries) are rich in bioactive polyphenolic compounds, which have been shown to lower inflammation and favorably impact metabolism. However, there is tremendous inter-individual variability in the bioavailability of polyphenolics and production of bioactive phenolic metabolites in the colon that depends, at least in part, on digestive metabolism by the gut microbiota. Little is known about the complex interactions among the gut microbiome, anti-inflammatory food metabolomic signatures, and human inflammation phenotypes. This study will utilize a systems-level approach to disentangle these complex interactions. The specific study objectives are as follows:

1. to determine the impact of Aronia supplementation on inflammation, metabolic health, and gut microbiome composition

2. to determine the static and dynamic metabolomic signature of Aronia based on an Aronia supplementation period and responses to a high-fat meal challenge

Description:

To meet these objectives, a randomized, double-blind, placebo-controlled clinical trial of Aronia versus placebo treatment for 28-30 days in human adults will be conducted. Pre- and post-intervention assessments will be made for the following variables: makeup of the gut microbiome (microbial species and relative abundance), gut metabolome, postprandial response of TG, inflammatory cytokines, and serum metabolome to a high-fat meal challenge (established inflammation stimulus), fasting serum glucose, lipid, insulin, inflammation markers and metabolome, blood pressure, and anthropometric measures including weight, body composition, waist circumference, and quantity of visceral adipose tissue. Physical activity, sedentary behavior, and habitual diet will be measured so that these variables can be used to characterize participants and aid in analysis and interpretation of data.

Procedures:

Postprandial lipidemic and inflammation responses: High-fat meal challenges with 40 to 100 g of dietary fat are an established laboratory test to measure both postprandial triglyceridemic and inflammation responses. Investigators have used a 50 g dose of fat delivered in the form of butter on toast on > 50 individuals because this particular dose is effective at discriminating between low versus high TG and inflammation responders. In brief, participants will report to the laboratory after an overnight fast, and blood samples will be collected before, and 1, 2, 4, and 6 hours following ingestion of the high-fat meal. Samples will be analyzed in real time for TG (and full lipid panel plus glucose) using a clinical chemistry analyzer (Piccolo xpress), while serum samples will be aliquoted and stored at -80 C until analysis for inflammatory cytokines, metabolomics, and insulin. Investigators will measure inflammatory cytokines (TNF-α, interleukin(IL)-1β, IL-6 IL-17, IL-23, and granulocyte macrophage colony stimulating factor (GM-CSF)) using high-sensitivity Luminex multiplexing technology (Bio-RadBio-Plex® 200 HTS) prepared by Millipore.

Dietary intervention: Participants will be randomized to either experimental (Aronia) or placebo-matched control group. The experimental supplement will consist of a once daily dose of 100 mL of Aronia juice. The placebo-matched control supplement will have no polyphenol content and will consist of 100 mL of the following mixture: black cherry Koolaid, blue and red food coloring, sucrose and sorbitol. This placebo will match the sugar content of the chokeberry juice. The daily dose of 100 mL for both groups is consumed once daily for duration of 28-30 day supplementation period. All participants will be instructed to avoid consumption of foods with polyphenolic content for the duration of the supplementation period. A list of disallowed foods will be provided for participants to reference.

Gut microbiome analysis: Bulk DNA will be extracted from fecal samples using the Powersoil® DNA Isolation Kit (Mo Bio Laboratories Inc.). DNA will be shipped overnight to the University of Michigan, Center for Microbial Systems, for Illumina MiSeq amplicon sequencing of the 16S V4 variable region. Raw sequencing reads will be processed and curated using the mothur (v.1.39.5) software package, following the mothur MiSeq standard operating procedure, potentially chimeric sequences will be identified and removed using the Uchime (v4.2.40) algorithm, and taxonomic classifications will be assigned using the Bayesian classifier of the Ribosomal Database Project, and operational taxonomic units (OTUs) will be assigned in mothur using the VSEARCH distance-based clustering algorithm at the 97% sequence similarity threshold.

Metabolomic analysis: Samples will be analyzed by high resolution liquid chromatography mass spectrometry (LCMS). Hydrophilic interaction chromatography (HILIC) and reverse-phase (RP) columns will be used for deep coverage. Metabolite identification will use fragmentation pattern matching, authentic standards and database matching with METLIN and the Human Metabome Database (HDB). Novel features of significant interest will be characterized with liquid chromatography mass spectrometry solid phase extraction nuclear magnetic resonance (LCMS-SPE-NMR). Pathway analysis will use XCMS and mummichog.

Dietary analysis: Long-term dietary habits may create adaptations that influence the response to the short-term supplementation of Aronia. This study will use the most recent version (2018) of the web-based Diet History Questionnaire (DHQ III), a food frequency questionnaire designed for adults 19 and older, developed by staff at the Risk Factor Monitoring and Methods Branch (RFMMB) of the NIH National Cancer Institute. The outputs of the DHQ III include carbohydrate constituents, carotenoids and tocopherols, dietary constituents from supplements, fats, fatty acids and cholesterol, macronutrients and energy, minerals, protein constituents, and vitamins are dietary constituents and food groups available in the DHQ III output files.

Statistical analysis: Two-sample t-tests to compare the difference between pre- and post-intervention assessments. Investigators will identify changes in the gut microbiome using the methods utilized in our preliminary research to identify characteristics of the gut microbiome that differentiate low versus high TG responders, and then use regression analysis to determine the level of variability in changes to the Aronia and control treatments explained by changes in relative abundance of gut microbial species. Investigators will identify changes in the gut and serum metabolomes, and then determine the metabolic pathways associated with the metabolomic changes to identify potential mechanisms underlying health impacts of Aronia supplementation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 13
• Est. completion date: August 18, 2019
• Est. primary completion date: August 18, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• 18-60 years

Exclusion Criteria:

• Individuals who are pregnant or have other health conditions that might make it difficult to participate in the study, including heart disease, diabetes, and hypertension

• Individuals who are unwilling or unable to complete multiple venipuncture collections.

• Individuals who have food allergies or sensitivities to berry fruits

• Individuals unwilling or unable to avoid foods on provided food list for the duration of the supplementation period.

• Individuals who have food allergies or dietary restrictions to any of the foods being used, including wheat, dairy, or Aronia berries (chokeberries)

• Individuals taking blood pressure, lipid-lowering, or anti-inflammatory medications

• Individuals who have taken antibiotics in previous 90 days

• Individuals who have food allergy or intolerance to red food dye

Related Conditions & MeSH terms

• Hypertriglyceridemia
• Inflammation
• Metabolic Diseases
• Metabolic Disorder

Intervention

Dietary Supplement:
• Aronia juice
Once daily dose of 100 mL of aronia juice

Other:
• Placebo
Once daily dose of 100 mL of placebo juice containing no polyphenols and matched to experimental Aronia juice in color, taste, and macronutrient content

Locations

Country	Name	City	State
United States	Nutrition Research Laboratory	Bozeman	Montana

Sponsors (1)

Lead Sponsor	Collaborator
Montana State University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Postprandial Serum Inflammatory Cytokine (tumor necrosis factor-alpha, interleukin-(IL)1beta, IL-6, IL-10, IL-17, IL-23, interferon-gamma, and granulocyte macrophage-colony stimulating factor; all in pg/ml) Response to High-fat Meal	Area under the curve for inflammatory cytokine (tumor necrosis factor-alpha, interleukin-(IL)1beta, IL-6, IL-10, IL-17, IL-23, interferon-gamma, and granulocyte macrophage-colony stimulating factor; all in pg/ml) concentrations after consuming a meal containing 50 g of fat	4 weeks
Primary	Peak Serum Cytokine (tumor necrosis factor-alpha, interleukin-(IL)1beta, IL-6, IL-10, IL-17, IL-23, interferon-gamma, and granulocyte macrophage-colony stimulating factor; all in pg/ml) Response to High-fat Meal	Greatest change in inflammatory cytokine (tumor necrosis factor-alpha, interleukin-(IL)1beta, IL-6, IL-10, IL-17, IL-23, interferon-gamma, and granulocyte macrophage-colony stimulating factor; all in pg/ml) concentration after consuming a meal containing 50 g of fat	4 weeks
Primary	Postprandial Serum Metabolomic Response to a High-fat Meal	Serum metabolome analysis before and 1, 2, 4, and 6 hours after consuming meal containing 50 g fat	4 weeks
Primary	Postprandial Serum Metabolite (untargeted) Response to High-fat Meal	Changes in concentrations of metabolites measured with untargeted liquid chromatography mass spectrometry (LCMS) metabolomic analysis after consuming a meal containing 50 g of fat	4 weeks
Primary	Fasting serum metabolites (untargeted)	Serum metabolome measured after an overnight fast	4 weeks
Primary	Gut microbiome composition	Relative abundance (operational taxonomic units/10,000 reads) of microbial taxa measured from fecal samples	4 weeks
Primary	Fasting Serum Triglycerides	Concentration of triglycerides in the serum after an overnight fast	4 weeks
Primary	Peak Serum Triglyceride Response to High-fat Meal	Greatest change in triglyceride concentration after consuming a meal containing 50 g of fat	4 weeks
Primary	Postprandial Serum Triglyceride Response to High-Fat Meal	Area under the curve for triglyceride concentration after consuming a meal containing 50 g of fat	4 weeks
Secondary	Blood pressure	Resting systolic and diastolic blood pressure (mmHg)	4 weeks
Secondary	Weight	Weight (kg)	4 weeks
Secondary	Height	Height (m)	4 weeks
Secondary	Body composition	Body composition (% fat, % lean)	4 weeks
Secondary	Waist circumference	Waist circumference (cm_)	4 weeks
Secondary	Visceral adipose tissue	Volume of visceral adipose tissue (L)	4 weeks
Secondary	Habitual Diet	Habitual dietary intake from past month report through a food frequency questionnaire for food, beverage, and supplement intake	4 weeks